Medifocus Inc. (TSXV-MFS)

Competitive advantage

Patent Protected Proprietary Technology Platform - 9 US allowed patents, 20 international patents and 34 patents pending.

APA system already FDA approved for other oncological indications.

Ability of the APA System to Treat All Forms of Breast Cancer and Other Cancers.

APA system provides volumetric heating to treat very large solid tumors.

Unique Category-III CPT Code to position for insurance reimbursement approval.   

APA system received the Investigational Testing Authorization (ITA) from Health Canada and the Investigational Device Exemption (IDE) from the Food and Drug Administration for conducting the pivotal phase III trial for breast cancer treatment in Canada and the United States.

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF.PK)
© 2007 - 2023 Medifocus. All Rights Reserved. Legal Disclaimers